Beyond the Headlines, Columns-Drugs & Supplements, March 2006

March 14, 2006

iPLEDGE Program Started to Educate Women About Risk of Pregnancy With Accutane WASHINGTON, D.C. - The Food and Drug Administration recently implemented the iPLEDGE program to educate women about the risk of becoming pregnant while taking Accutane, an acne drug manufactured by Hoffman-La Roche. The FDA said the program was established on March 1 to reduce the risk of inadvertent pregnancy exposure by tightly linking negative pregnancy testing with dispensing of Accutane (isotretinoin). iPLEDGE is a computer-based risk management program designed to further the public health goal of eliminating fetal exposure to isotretinoin through a … Subscribe Now Purchase Article for $40.00 Registered User Log In Email Address Password Login Forgot your username or password? UPCOMING CONFERENCES HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates May 29, 2024 - Salt Lake City, UT The Grand America Hotel MORE DETAILS HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone June 27, 2024 - Buffalo, NY The Richardson Hotel Buffalo MORE DETAILS Sign Up For Email Alerts × Email address Publications Asbestos Benzene & Emerging Toxic Torts Litigation Camp Lejeune & Water Contamination Drugs & Medical Devices MDL Mass Tort & Class Action Monitor Reinsurance & Arbitration Talcum Powder Litigation Report Close Submit